Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.050 AUD
−18.77 M AUD
52.12 K AUD
362.43 M
About Paradigm Biopharmaceuticals Ltd.
Sector
Industry
CEO
Paul John Rennie
Website
Headquarters
Melbourne
Founded
2014
ISIN
AU000000PAR5
FIGI
BBG009QNWX30
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PAR is 0.360 AUD — it has increased by 1.49% in the past 24 hours. Watch Paradigm Biopharmaceuticals Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange Paradigm Biopharmaceuticals Ltd. stocks are traded under the ticker PAR.
PAR stock has risen by 19.30% compared to the previous week, the month change is a 17.24% rise, over the last year Paradigm Biopharmaceuticals Ltd. has showed a 84.62% increase.
We've gathered analysts' opinions on Paradigm Biopharmaceuticals Ltd. future price: according to them, PAR price has a max estimate of 2.10 AUD and a min estimate of 0.65 AUD. Watch PAR chart and read a more detailed Paradigm Biopharmaceuticals Ltd. stock forecast: see what analysts think of Paradigm Biopharmaceuticals Ltd. and suggest that you do with its stocks.
PAR stock is 7.35% volatile and has beta coefficient of 3.51. Track Paradigm Biopharmaceuticals Ltd. stock price on the chart and check out the list of the most volatile stocks — is Paradigm Biopharmaceuticals Ltd. there?
Today Paradigm Biopharmaceuticals Ltd. has the market capitalization of 137.95 M, it has increased by 19.64% over the last week.
Yes, you can track Paradigm Biopharmaceuticals Ltd. financials in yearly and quarterly reports right on TradingView.
Paradigm Biopharmaceuticals Ltd. is going to release the next earnings report on Feb 25, 2026. Keep track of upcoming events with our Earnings Calendar.
PAR net income for the last half-year is −12.85 M AUD, while the previous report showed −5.92 M AUD of net income which accounts for −116.86% change. Track more Paradigm Biopharmaceuticals Ltd. financial stats to get the full picture.
No, PAR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Paradigm Biopharmaceuticals Ltd. EBITDA is −22.83 M AUD, and current EBITDA margin is −43.81 K%. See more stats in Paradigm Biopharmaceuticals Ltd. financial statements.
Like other stocks, PAR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Paradigm Biopharmaceuticals Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Paradigm Biopharmaceuticals Ltd. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Paradigm Biopharmaceuticals Ltd. stock shows the sell signal. See more of Paradigm Biopharmaceuticals Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.